FDA Suggests Endpoint Validator for LGS Artificial Pancreas

The FDA is recommending that readings from continuous glucose monitors (CGM) be used to determine if trials for artificial pancreas devices are reaching their endpoints, despite its concerns about the accuracy of the method in this context.
Devices & Diagnostics Letter